Cantor Fitzgerald Reiterates “Overweight” Rating for Alumis (NASDAQ:ALMS)

Alumis (NASDAQ:ALMS)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports.

A number of other brokerages have also weighed in on ALMS. Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price (down previously from $19.00) on shares of Alumis in a research report on Thursday. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $26.00.

Alumis Stock Performance

Shares of NASDAQ:ALMS traded down $0.04 on Thursday, hitting $4.33. The company’s stock had a trading volume of 4,156 shares, compared to its average volume of 170,166. Alumis has a 1 year low of $4.24 and a 1 year high of $13.53. The company has a 50-day simple moving average of $5.84 and a 200 day simple moving average of $8.69.

Hedge Funds Weigh In On Alumis

Hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. acquired a new position in Alumis during the third quarter worth $1,160,000. BNP Paribas Financial Markets acquired a new position in Alumis during the 3rd quarter worth about $27,000. MetLife Investment Management LLC purchased a new position in Alumis in the third quarter valued at $89,000. Maven Securities LTD boosted its holdings in shares of Alumis by 100.0% in the 3rd quarter. Maven Securities LTD now owns 50,000 shares of the company’s stock valued at $534,000 after buying an additional 25,000 shares in the last quarter. Finally, Samsara BioCapital LLC purchased a new position in shares of Alumis in the 3rd quarter valued at approximately $34,886,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.